| |
News from Yahoo! Finance Apr.11, 2007
PerkinElmer Selected by Capital Health
of Alberta to Supply Expert Solutions for Expanded Newborn Screening
Program
Tandem Mass Spectrometers,
Reagents, and Software Now Used in Canadian Province's Enhanced
Neonatal Screening Program
WALTHAM, MASS., April 11 /CNW/ -
PerkinElmer, Inc. (NYSE: PKI - News), a global leader in Health
Sciences and Photonics, today announced a multi-year, multi-million
dollar agreement with Capital Health in Edmonton, Alberta, Canada,
that provides instruments, reagents, software and screening
expertise to enhance its neonatal screening program. The expanded
program, which now includes screening for 17 metabolic conditions
in newborns, began province-wide on April 1, 2007.
Under the terms of the agreement, signed in the second half of 2006,
Capital Health has purchased tandem mass spectrometry systems,
reagent kits and PerkinElmer's industry-leading Specimen Gate(R)
screening software to expand Alberta's newborn screening for
inherited metabolic disorders (IMDs) including cystic fibrosis.
Alberta is the first province in Canada to screen all newborns for
cystic fibrosis.
"We are pleased to partner with Capital Health to support its
state-of-the-art newborn screening program," said Robert F. Friel,
president of PerkinElmer Life and Analytical Sciences. "PerkinElmer's
leading technology is designed to allow these early detection
programs to identify infants at risk for devastating metabolic
disorders, enabling early intervention and treatment to save lives
and improve quality of life."
Capital Health's Laboratory at the University of Alberta Hospital
provides neonatal screening services for approximately 42,000
babies born in Alberta annually. Capital Health is one of the
largest academic health regions in Canada.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements relating to estimates and
projections of future earnings per share and revenue growth and
other financial results, developments relating to our customers and
end-markets, and plans concerning business development opportunities.
Words such as "believes," "intends," "anticipates," "plans," "expects,"
"projects," "forecasts," "will" and similar expressions, and
references to guidance, are intended to identify forward-looking
statements. Such statements are based on management's current
assumptions and expectations and no assurances can be given that our
assumptions or expectations will prove to be correct. A number of
important risk factors could cause actual results to differ
materially from the results described, implied or projected in any
forward-looking statements. These factors include, without
limitation: (1) our failure to introduce new products in a timely
manner; (2) our ability to execute acquisitions and license
technologies, or to successfully integrate acquired businesses and
licensed technologies into our existing business or to make them
profitable; (3) our failure to protect adequately our intellectual
property; (4) the loss of any of our licenses or licensed rights;
(5) our ability to compete effectively; (6) fluctuation in our
quarterly operating results and our ability to adjust our operations
to address unexpected changes; (7) our ability to produce an
adequate quantity of products to meet our customers' demands; (8)
our failure to maintain compliance with applicable government
regulations; (9) regulatory changes; (10) economic, political and
other risks associated with foreign operations; (11) our ability to
retain key personnel; (12) restrictions in our credit agreement;
(13) our ability to realize the full value of our intangible assets;
and (14) other factors which we describe under the caption "Risk
Factors" in our most recent annual report on Form 10-K and in our
most recent quarterly report on Form 10-Q and in our other filings
with the Securities and Exchange Commission. We disclaim any
intention or obligation to update any forward-looking statements as
a result of developments occurring after the date of this press
release.
Other Information
Health Sciences end markets include genetic screening, environmental,
service, biopharma, and medical imaging. Photonics markets include
sensors and specialty lighting.
PerkinElmer, Inc. is a global technology leader driving growth and
innovation in Health Sciences and Photonics markets to improve the
quality of life. The Company reported revenues of $1.55 billion in
2006, has 8,500 employees serving customers in more than 125
countries, and is a component of the S&P 500 Index. Additional
information is available through
www.perkinelmer.com or 1-877-PKI-NYSE.
For further information
PerkinElmer, Inc. Investor Contact: Steven Delahunt, 781-663-5677 or
Media Contact: Kevin Lorenc, 781-663-5701
http://biz.yahoo.com/cnw/070411/perkinelmer.html?.v=1
<----back |
|